Sarepta Therapeutics
SRPT
411 hedge funds and large institutions have $10.2B invested in Sarepta Therapeutics in 2022 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 125 increasing their positions, 129 reducing their positions, and 41 closing their positions.
105% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 41
51% more call options, than puts
Call options by funds: $371M | Put options by funds: $246M
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
10% more capital invested
Capital invested by funds: $9.25B → $10.2B (+$944M)
10% more funds holding
Funds holding: 375 → 411 (+36)
3% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 129
6.85% less ownership
Funds ownership: 96.73% → 89.88% (-6.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$61.2M |
| 2 |
JP Morgan Chase
New York
|
+$60.5M |
| 3 |
PA
Perceptive Advisors
New York
|
+$45.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$35.2M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$34.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$803M |
| 2 |
Alkeon Capital Management
New York
|
-$64.6M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$45.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$42.8M |
SRPT Hedge Fund Activity: Q4 2022 in Review
411 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2022, worth a combined $10.2B — up 10% from $9.25B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new SRPT positions and 41 closed out — a net gain of 43 holders — while 125 added to existing stakes and 129 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $61.2M. The largest seller was Janus Henderson Group, cutting an estimated $803M.
- 411 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2022, up from 375 in Q3 2022.
- Funds reported $10.2B of Sarepta Therapeutics stock for Q4 2022, up 10% quarter-over-quarter.
- 84 funds opened new Sarepta Therapeutics positions in Q4 2022 and 41 closed out, a net change of +43 holders.
- The largest Sarepta Therapeutics buyer in Q4 2022 was Deep Track Capital, an estimated $61.2M added.
- The largest Sarepta Therapeutics seller in Q4 2022 was Janus Henderson Group, an estimated $803M sold.
Based on aggregated 13F filings for Q4 2022.